Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Trifarotene
Другие языки:

Trifarotene

Подписчиков: 0, рейтинг: 0

Trifarotene
Trifarotene.svg
Clinical data
Trade names Aklief
Other names CD5789
AHFS/Drugs.com Monograph
MedlinePlus a620004
License data
Pregnancy
category
  • AU: D
  • Contraindicated
Routes of
administration
Topical
Drug class Skin and mucous membrane agents
ATC code
Legal status
Legal status
Identifiers
  • 4-[3-(3-tert-Butyl-4-pyrrolidin-1-ylphenyl)-4-(2-hydroxyethoxy)phenyl]benzoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.278.901
Chemical and physical data
Formula C29H33NO4
Molar mass 459.586 g·mol−1
3D model (JSmol)
  • CC(C)(C)c1cc(-c2cc(-c3ccc(C(=O)O)cc3)ccc2OCCO)ccc1N1CCCC1
  • InChI=1S/C29H33NO4/c1-29(2,3)25-19-23(10-12-26(25)30-14-4-5-15-30)24-18-22(11-13-27(24)34-17-16-31)20-6-8-21(9-7-20)28(32)33/h6-13,18-19,31H,4-5,14-17H2,1-3H3,(H,32,33)
  • Key:MFBCDACCJCDGBA-UHFFFAOYSA-N

Trifarotene, sold under the brand name Aklief, is a medication for the topical treatment of acne vulgaris. It is a retinoid; more specifically, it is a fourth generation selective retinoic acid receptor (RAR)-γ agonist.

Trifarotene was granted orphan drug designation for the treatment of congenital ichthyosis by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). It was approved for medical use in the United States in October 2019. In December 2019, its labelling and package leaflet text received a decentralised approval for 16 European countries.

Medical uses

In the United States, trifarotene is indicated for the topical treatment of acne vulgaris in people nine years of age and older.

In both Canada and Australia, it is indicated for the topical treatment of acne vulgaris of the face and/or the trunk in people twelve years of age and older.

Society and culture

Legal status

Trifarotene was approved for medical use in the United States in October 2019, in Canada in November 2019, and in Australia in January 2021.

External links


Новое сообщение